Monica Shah, MD, IQVIA, Washington, D.C., provides a brief overview of innovations within the cardiovascular cell and gene therapy sectors. Dr Shah highlights cell therapies treating acute myocardial infarctions, and heart failure, as well as gene therapies treating hypertrophic cardiomyopathy. She additionally discusses novel approaches in conducting clinical trials including decentralized clinical trials and alternative recruitment strategies. Biomarkers and artificial intelligence will also impact future trials by effectively determining patients who will benefit from these treatments the most. This interview took place at Meeting on the Mesa 2021.